Natera at the American Society of Clinical Oncology (ASCO®) Annual Meeting 2026

Natera will be presenting 35+ abstracts at ASCO®, including impactful data releases across multiple indications and settings.

On-site, we will be unveiling exciting portfolio updates, showcasing real-world data (RWD) demos at our Biopharma Partnerships Booth #13041, and hosting a private evening yacht event. Please reach out to our biopharma partnership team if you’re interested in attending.

Stop by our booth to learn more about the only ultrasensitive MRD portfolio powered by phased variant technology.

Natera’s 35+ abstracts at ASCO®

With an unmatched commercial footprint, superior clinical evidence, and deep regulatory expertise, Natera serves as a trusted partner across every stage of drug development to restore and preserve life for cancer patients worldwide.

We’d love to connect. Schedule time with our biopharma team to explore partnership opportunities at pharma@natera.com

Natera Data Hightlights

Title: Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.

Presenter: Mitsuru Yokota, MD, PhD

Date / Time: May 30, 2026, 8:00-9:00 AM

Abstract #: 102

Presentation Details: Oral Presentation – Clinical Science Symposium – ctDNA in Clinical Practice: From Detection to Clinical Decision-Making

Title: Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics.

Presenter: Eiji Oki, MD, PhD, FACS

Date / Time: May 31, 2026, 8:00-11:00 AM

Abstract #: 3501

Presentation Details: Oral Presentation – Oral Abstract Session – Gastrointestinal Cancer—Colorectal and Anal

Title: Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).

Presenter: Hannah Ruth Robinson, MD

Date / Time: June 2, 2026, 8:00 AM – 9:30 AM

Abstract #: 3516

Presentation Details: Rapid Oral Presentation – Gastrointestinal Cancer—Colorectal and Anal

Title: Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis

Presenter: Scott Kopetz, MD, PhD, FASCO

Date / Time: June 1, 2026, 9:00 AM-12:00 PM

Abstract #: 11177 / Poster Board: #160

Presentation Details: Poster Session – Quality Care/Health Services Research

Saturday May 30

Title: Impact of postsurgical circulating tumor DNA (ctDNA) dynamics on eligibility of colorectal cancer (CRC) patients for randomized ALTAIR trial: Implications for treat-on-molecular-recurrence (TOMR) trials.

Presenter: Hideaki Bando, MD, PhD

Date / Time: May 30, 2026, 9:00 AM-12:00 PM

Abstract #: 3628 / Poster Board: #395

Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal

Title: Performance of a tissue-free, molecular residual disease assay in colorectal, breast, and lung cancers from circulating tumor DNA.

Presenter: Princy Parsana, PhD

Date / Time: May 30, 2026, 1:30 – 4:30 PM

Abstract #: 3042 / Poster Board: #179

Presentation Details: Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Title: Correlation of presurgical circulating tumor DNA (ctDNA) levels with pathologic (p) stage and lymph node (LN) burden in localized colon cancer.

Presenter: Masahito Kotaka, MD, PhD

Date / Time: May 30, 2026, 1:30-4:30 PM

Abstract #: 3048 / Poster Board: #185

Presentation Details: Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Title: Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: Exploratory analyses from the phase 2 EPOC2003 study.

Presenter: Akihito Kawazoe, MD

Date / Time: May 30, 2026, 1:30-4:30 PM

Abstract #: 3129 / Poster Board: #266

Presentation Details: Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Title: Prognostic value of perioperative ctDNA monitoring in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemotherapy (NAC) and surgery.

Presenter: Akinori Watanabe, MD, PhD

Date / Time: May 30, 2026, 9:00 AM-12:00 PM

Abstract #: 4094 / Poster Board: #77

Presentation Details: Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Title: Comparison of longitudinal circulating tumor DNA (ctDNA) and carcinoembryonic antigen (CEA) for post-operative risk stratification in colorectal cancer (CRC).

Presenter: Eiji Oki, MD, PhD, FACS

Date / Time: May 30, 2026, 9:00 AM-12:00 PM

Abstract #: 3637 / Poster Board: #404

Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal

Title: Early ctDNA dynamics assessed by a personalized whole-genome sequencing-based assay as a predictor of outcomes with immune checkpoint blockade in advanced melanoma

Presenter: Mora Guardamagna, MD, PhD, MSc

Date / Time: May 30, 2026, 1:30-4:30 PM

Abstract #: 3053 / Poster Board: #190

Presentation Details: Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Title: Consensus molecular subtypes, mutational features, and circulating tumor DNA dynamics in colorectal cancer: A real-world clinico-genomic analysis.

Presenter: Imad Shureiqi, MD, MS

Date / Time: May 30, 2026, 9:00 AM – 12:00 PM

Abstract #: 3652 / Poster Board: #419

Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal

Title: Ultrasensitive tumor-informed ctDNA MRD detection to identify metastatic relapse and as predictor of recurrence-free survival following resection of early-stage NSCLC.

Presenter: Fernando Pikabea Díaz, MD

Date / Time: May 30, 2026, 1:30 – 4:30 PM

Abstract #: 3060 / Poster Board: #197

Presentation Details: Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Title: Prevalence of CDH1 germline variants in gastric cancer patients with exome-inferred ancestry.

First Author: Skylar Nahi

Date / Time: May 30, 2026, 9:00 AM – 12:00 PM

Abstract #: 4073 / Poster Board: #56

Presentation Details: Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Title: Intratumoral dendritic cell (DC1) therapy prior to neoadjuvant chemotherapy in HER2-positive breast cancer (NATASHA trial).

Presenter: Hyo S. Han, MD

Date / Time: May 30, 2026, 1:30 – 4:30 PM

Abstract #: 2594 / Poster Board: #384

Presentation Details: Poster Session – Developmental Therapeutics—Immunotherapy

Title: A large-scale, multi-target deep learning model for virtual genomic and molecular risk profiling in colorectal cancer.

Presenter: Erik N. Bergstrom, PhD, BS

Date / Time: May 30, 2026, 9:00 AM – 12:00 PM

Abstract #: 3526 / Poster Board: #280

Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal

Sunday May 31

Title: Longitudinal tumor-informed ctDNA monitoring and clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin ± pembrolizumab.

Presenter: Adanma Ayanambakkam

Date / Time: May 31, 2026, 9:00 AM-12:00 PM

Abstract #: 4569 / Poster Board: #48

Presentation Details: Poster Session – Genitourinary Cancer—Kidney and Bladder

Title: Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA–guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).

Presenter: Joaquim Bellmunt

Date / Time: May 31, 2026, 9:00 AM-12:00 PM

Abstract #: 4627 / Poster Board: #106

Presentation Details: Poster Session – Genitourinary Cancer—Kidney and Bladder

Title: Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).

Presenter: Mohammad Jad Moussa, MD, MSc

Date / Time: May 31, 2026, 9:00 AM-12:00 PM

Abstract #: 4582 / Poster Board: #61

Presentation Details: Poster Session – Genitourinary Cancer—Kidney and Bladder

Title: ctDNA clearance durability and progression-free survival in unresectable or metastatic cutaneous malignancies.

First Author: Joshua Espinola

Date / Time: May 31, 2026, 9:00 AM-12:00 PM

Abstract #: 9591 / Poster Board: #307

Presentation Details: Poster Session – Melanoma/Skin Cancers

Title: Longitudinal monitoring for post-surgical molecular residual disease in patients with stage I–IIIB melanoma using a whole-genome sequencing–based ctDNA assay.

First Author: Karam Khaddour

Date / Time: May 31, 2026, 9:00 AM-12:00 PM

Abstract #: 9577 / Poster Board: #293

Presentation Details: Poster Session – Melanoma/Skin Cancers

Title: Circulating tumor DNA dynamics following molecularly targeted therapy for non–small cell lung cancer.

Presenter: Justin Jee, MD, PhD

Date / Time: May 31, 2026, 9:00 AM – 12:00 PM

Abstract #: 8652 / Poster Board: #442

Presentation Details: Poster Session – Lung Cancer—Non-Small Cell Metastatic

Monday June 1

Title: Integrating Personalized ctDNA into Clinical Surveillance of Soft Tissue Sarcoma: Performance, Timing, and Histologic Insights

Presenter: Amrit Paudel, MD

Date / Time: June 1, 2026, 1:30-4:30 PM

Abstract #: 11581 / Poster Board: #371

Presentation Details: Poster Session – Sarcoma

Title: Post-treatment ctDNA monitoring using a tumor-informed whole-genome sequencing-based assay in homologous recombination–proficient ovarian cancer

Presenter: Sophie Blakey-Cheung, MD

Date / Time: June 1, 2026, 9:00 AM – 12:00 PM

Abstract #: 5592 / Poster Board: #258

Presentation Details: Poster Session – Gynecologic Cancer

Title: Prevalence of microsatellite stable Lynch syndrome and universal germline testing: A pan-cancer analysis of 246,694 patients

Presenter: Casey Cosgrove, MD

Date / Time: June 1, 2026, 1:30 – 4:30 PM

Abstract #: 10613 / Poster Board: #574

Presentation Details: Poster Session – Prevention, Risk Reduction, and Genetics

Title: Measurable residual disease (MRD) by circulating tumor (ct) DNA in patients (pt) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucel (liso-cel) in TRANSCEND FL

Presenter: Sahar Ansari

Date / Time: June 1, 2026, 9:00 AM – 12:00 PM

Abstract #: 7025 / Poster Board: #523

Presentation Details: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Title: Phase 2 trial of lisocabtagene maraleucel for minimal residual disease in patients with large B-cell lymphoma

Presenter: Dai Chihara, MD, PhD

Date / Time: June 1, 2026, 9:00 AM – 12:00 PM

Abstract #: TPS7107 / Poster Board: #601a

Presentation Details: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Title: ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer

Presenter: Payal Deepak Shah, MD

Date / Time: June 1, 2026, 1:30 – 4:30 PM

Abstract #: TPS644 / Poster Board: #128a

Presentation Details: Poster Session – Breast Cancer—Local/Regional/Adjuvant

Title: PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC with Residual Disease

Presenter: Yara Abdou, MD, MS

Date / Time: June 1, 2026, 1:30 – 4:30 PM

Abstract #: TPS647 / Poster Board: #129b

Presentation Details: Poster Session – Breast Cancer—Local/Regional/Adjuvant

Title: SIGNAL-ER-101: Signatera-guided CDK4/6 inhibitor therapy in breast cancer

Presenter: Marla Lipsyc-Sharf, MD

Date / Time: June 1, 2026, 1:30 – 4:30 PM

Abstract #: TPS648 / Poster Board: #130a

Presentation Details: Poster Session – Breast Cancer—Local/Regional/Adjuvant

Day to be determined

Title: Phase 2 study of adjuvant botensilimab in combination with balstilimab in patients with microsatellite-stable colorectal cancer and persistent circulating tumor DNA following surgery and chemotherapy

Presenter: Neil Howard Segal, MD, PhD

Date / Time: TBD

Abstract #: TPS3689 / Poster Board: #447b

Presentation Details: Poster Session – Gastrointestinal Cancer—Colorectal and Anal

Title: Optimal timing of circulating tumor DNA (ctDNA) dynamics to prognosticate immune checkpoint inhibitors (ICI) efficacy in patients with advanced stage melanoma

Presenter: Vincent T. Ma, MD

Date / Time: TBD

Abstract #: 9534 / Poster Board: #250

Presentation Details: Poster Session – Melanoma/Skin Cancers

Title: Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma

Presenter: Alyssa K. Steimle, MD

Date / Time: TBD

Abstract #: 9533 / Poster Board: #249

Presentation Details: Poster Session – Melanoma/Skin Cancers

Title: Circulating tumor DNA (ctDNA) as a biomarker for pathologic response and clinical outcomes in patients with cutaneous squamous cell carcinoma (CSCC) receiving neoadjuvant anti–PD-1 therapy

Presenter: Luke Skyler Vest, MD

Date / Time: TBD

Abstract #: 9587 / Poster Board: #303

Presentation Details: Poster Session – Melanoma/Skin Cancers

Title: Whole-genome sequencing–based ctDNA testing for post-surgical monitoring and early detection of recurrence or progression in uterine cancer

Presenter: Abigail Barger, MD

Date / Time: TBD

Abstract #: 5623 / Poster Board: #289

Presentation Details: Poster Session – Gynecologic Cancer

Online Publications

Title: Circulating tumor DNA (ctDNA) monitoring of high-risk breast cancer patients: A retrospective descriptive analysis in a community setting

First Author: Candice Thompson, MD

Abstract #: e12606

Presentation Details: Publication Only – Breast Cancer—Local/Regional/Adjuvant

Title: Cross-platform concordance between tumor-informed and tumor-naive ctDNA MRD assays in early-stage NSCLC: A paired-sample pilot comparison of Signatera and Guardant Reveal

First Author: Oleg Gligich, MD

Abstract #: e20082

Presentation Details: Publication Only – Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Title: Prognostic significance of ctDNA detection at the time of relapse during melanoma surveillance

First Author: Soham Ali, MD

Abstract #: e21543

Presentation Details: Publication Only – Melanoma/Skin Cancers

Title: Real-world clinical impact and prognostic utility of circulating tumor DNA in stage I–IV non–small cell lung cancer

First Author: Fernando Poli, MD

Abstract #: e20091

Presentation Details: Publication Only – Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Title: Clinical and molecular features of patients with PIK3CA-mutant (PIK3CAm) ER+/HER2− breast cancer with detectable circulating tumor DNA (ctDNA) in early breast cancer (eBC)

First Author: Niharika Duggirala, BS

Abstract #: e12609

Presentation Details: Publication Only – Breast Cancer—Local/Regional/Adjuvant

Title: Tumor-informed ctDNA as a biomarker of outcomes following stereotactic body radiotherapy in metastatic urothelial carcinoma

First Author: Marina Andreadis

Abstract #: e16590

Presentation Details: Publication Only – Genitourinary Cancer—Kidney and Bladder

To learn more this data or about partnering with Natera, reach out to our Biopharma Partnerships team

Speak with an expert today

Patient Testimonial

“… if I wouldn’t have had this Signatera™ test, it would have progressed to the point where a liver ablation was not an option. My liver surgeon [said] you’re a year ahead of the game because of the test.”

How can Signatera™ support your clinical trials?

Contact us to learn more

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

Not sponsored, endorsed, or accredited by the American Society of Clinical Oncology (ASCO®).